Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials

On Sunday, Vertex Pharmaceuticals Incorporated VRTX announced multiple program updates, including:In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates across major markets ...